(2012) 41:195–205. doi:10.1097/MPA.0b013e31822398c6 97. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identiﬁes the patient-speciﬁc CD8 +tumor-reactive repertoire inﬁltrating human tumors. J Clin Invest. (2014) 124:2246–59. doi: 10.1172/JCI 73639 98. Fu J, Malm I-J, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Pre clinical evidence that PD1 blockade cooperates with cancer vaccine TEGV AX to elicit regression of established tumors. Cancer Res. (2014) 74:4042–52. doi:10.1158/0008-5472.CAN-13-2685 99. Sierro SR, Donda A, Perret R, Guillaume P, Yagita H, Levy F, et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-t umor immunity. EurJImmunol. (2011)41:2217–28.doi:10.1002/eji.201041235 100. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD- 1/PD-L1 blockade together with vaccine therapy facilitates eﬀe ctor T- cell inﬁltration into pancreatic tumors. J Immunother. (2015) 38:1–11. doi:10.1097/CJI.0000000000000062 101. Morse MA, Lyerly HK. Checkpoint blockade in combination with c ancer vaccines. Vaccine.(2015)33:7377–85.doi:10.1016/j.vaccine.2015.10.057 102. Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Eng ert A, et al. Dendritic cell based tumor vaccination in prostate and rena l cell cancer: a systematic review and meta-analysis. PLoS ONE. (2011) 6:e18801. doi:10.1371/journal.pone.0018801 103.